Emerging Therapies for Myasthenia Gravis

Pritikanta Paul, MD, is an Assistant Professor in the Department of Neurology and Rehabilitation at University of Illinois at Chicago, and a neurologist with UI Health. Here Dr. Paul reviews new therapies that have been and are being developed to treat the autoimmune disease myasthenia gravis. He explains terms like “complement inhibitor” and “Fc receptor inhibitor” and addresses treatment options such as Ultomiris, Soliris, Vyvgart, as well as emerging therapies that target B cells, T cells, and other disease pathways.